{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:11:35Z","timestamp":1790262695708,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,2,17]],"date-time":"2014-02-17T00:00:00Z","timestamp":1392595200000},"content-version":"vor","delay-in-days":1569,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","oarsijournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoarthritis and Cartilage"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.joca.2009.04.009","type":"journal-article","created":{"date-parts":[[2009,4,23]],"date-time":"2009-04-23T04:55:52Z","timestamp":1240462552000},"page":"1393-1401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["OA clinical trials: current targets and trials for OA. Choosing molecular targets: what have we learned and where we are headed?"],"prefix":"10.1016","volume":"17","author":[{"given":"M.-P.","family":"Hellio Le Graverand-Gastineau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.joca.2009.04.009_bib1","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1002\/art.22160","volume":"54","author":"Bingham","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2009.04.009_bib2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.joca.2007.06.011","article-title":"Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials","volume":"16","author":"Bruyere","year":"2008","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2009.04.009_bib3","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1002\/1529-0131(200111)44:11<2539::AID-ART434>3.0.CO;2-T","article-title":"ECHODIAH Investigators Study Group. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in OA of the hip","volume":"44","author":"Dougados","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2009.04.009_bib4","unstructured":"CPMP Points to Consider \u2013 Clinical Investigation of Medicinal Products Used in the Treatment of OA \u2013 7\/98."},{"key":"10.1016\/j.joca.2009.04.009_bib6","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/art.21122","article-title":"Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial","volume":"52","author":"Brandt","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2009.04.009_bib7","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1136\/ard.2007.077834","article-title":"Head-to-head comparison of the Lyon schuss and fixed flexion radiographic techniques. Long-term reproducibility in normal knees and sensitivity to change in osteoarthritic knees","volume":"67","author":"Hellio Le Graverand","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2009.04.009_bib8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/rheumatology\/41.2.142","article-title":"Relevant change in radiological progression in patients with hip osteoarthritis. I. Determination using predictive validity for total hip arthroplasty","volume":"41","author":"Maillefert","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.joca.2009.04.009_bib9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/BOR.0b013e328248b4be","article-title":"Imaging of knee osteoarthritis: data beyond the beauty","volume":"19","author":"Eckstein","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.joca.2009.04.009_bib10","article-title":"Change in regional cartilage morphology and joint space width in osteoarthritis participants versus healthy controls \u2013 a multicenter study using 3.0 Tesla MRI and Lyon schuss radiography","author":"Hellio Le Graverand","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2009.04.009_bib11","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1302\/0301-620X.80B5.0800907","article-title":"Dupuytren's disease and frozen shoulder induced by treatment with a MMP inhibitor","volume":"80","author":"Hutchinson","year":"1998","journal-title":"J Bone Joint Surg Br"},{"key":"10.1016\/j.joca.2009.04.009_bib12","doi-asserted-by":"crossref","first-page":"27781","DOI":"10.1074\/jbc.M703286200","article-title":"Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia","volume":"282","author":"Johnson","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.joca.2009.04.009_bib13","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/ard.2006.063354","article-title":"Neurovascular invasion at the osteochondral junction and in osteophytes in osteoarthritis","volume":"66","author":"Suri","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2009.04.009_bib14","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/1529-0131(200108)44:8<1808::AID-ART318>3.0.CO;2-B","article-title":"Formation and phenotype of cell clusters in osteoarthritic meniscus","volume":"44","author":"Hellio Le Graverand","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2009.04.009_bib15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/joca.2000.0350","article-title":"Early changes in lapine menisci during osteoarthritis development: part I: cellular and matrix alterations","volume":"9","author":"Hellio Le Graverand","year":"2001","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2009.04.009_bib16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1053\/joca.2000.0351","article-title":"Early changes in lapine menisci during osteoarthritis development: part II: molecular alterations","volume":"9","author":"Hellio Le Graverand","year":"2001","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2009.04.009_bib17","first-page":"2449","article-title":"Concomitant therapy: an outcome variable for musculoskeletal disorders? Part 2: total joint replacement in osteoarthritis trials","volume":"32","author":"Maillefert","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.joca.2009.04.009_bib18","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.joca.2007.12.016","article-title":"The development of a short measure of physical function for hip OA HOOS-physical function shortform (HOOS-PS): an OARSI\/OMERACT initiative","volume":"16","author":"Davis","year":"2008","journal-title":"Osteoarthritis Cartilage"},{"issue":"4","key":"10.1016\/j.joca.2009.04.009_bib19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.joca.2007.12.015","article-title":"Development and preliminary psychometric testing of a new OA pain measure\u2014an OARSI\/OMERACT initiative","volume":"16","author":"Hawker","year":"2008","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2009.04.009_bib20","first-page":"1432","article-title":"OMERACT\/OARSI initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis","volume":"34","author":"Gossec","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.joca.2009.04.009_bib21","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/1529-0131(199906)42:6<1159::AID-ANR12>3.0.CO;2-Q","article-title":"Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions","volume":"42","author":"Manicourt","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2009.04.009_bib22","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/1529-0131(199807)41:7<1275::AID-ART19>3.0.CO;2-T","article-title":"Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase","volume":"41","author":"Pelletier","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2009.04.009_bib23","first-page":"2002","article-title":"Selective inhibition of iNOS in experimental OA is associated with reduction in tissue levels of catabolic factors","volume":"26","author":"Pelletier","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.joca.2009.04.009_bib24","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/1529-0131(200006)43:6<1290::AID-ANR11>3.0.CO;2-R","article-title":"Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: possible link with the reduction in chondrocyte apoptosis and caspase 3 level","volume":"43","author":"Pelletier","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2009.04.009_bib25","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/1529-0131(199807)41:7<1266::AID-ART18>3.0.CO;2-Y","article-title":"Chondrocyte apoptosis and nitric oxide production during experimentally induced osteoarthritis","volume":"41","author":"Hashimoto","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2009.04.009_bib26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1053\/joca.2000.0351","article-title":"Early changes in lapine menisci during osteoarthritis development part II: molecular alterations","volume":"9","author":"Hellio Le Graverand","year":"2000","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2009.04.009_bib27","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S0736-0266(01)00023-7","article-title":"Chondrocyte apoptosis and regional differential expression of nitric oxide in the medial meniscus following partial meniscectomy","volume":"19","author":"Kobayashi","year":"2001","journal-title":"J Orthop Res"},{"key":"10.1016\/j.joca.2009.04.009_bib28","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1053\/joca.1999.0228","article-title":"Animal models of arthritis in NOS2-deficient mice","volume":"7","author":"van den Berg","year":"1999","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2009.04.009_bib29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0022-1759(00)00302-1","article-title":"Analysis of collagenase-cleavage of type II collagen using a neoepitope ELISA","volume":"247","author":"Downs","year":"2001","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.joca.2009.04.009_bib30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jim.2004.09.005","article-title":"The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases","volume":"294","author":"Poole","year":"2004","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.joca.2009.04.009_bib31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1172\/JCI10564","article-title":"Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice","volume":"107","author":"Neuhold","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.joca.2009.04.009_bib32","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1042\/bj3050799","article-title":"Monoclonal antibodies that specifically recognize neoepitope sequences generated by \u2018aggrecanase\u2019 and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro","volume":"305","author":"Hughes","year":"1995","journal-title":"Biochem J"},{"key":"10.1016\/j.joca.2009.04.009_bib33","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/1529-0131(199906)42:6<1128::AID-ANR9>3.0.CO;2-2","article-title":"Kinetics of aggrecanase- and metalloproteinase-induced neoepitopes in various stages of cartilage destruction in murine arthritis","volume":"42","author":"van Meurs","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2009.04.009_bib34","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nature03369","article-title":"Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis","volume":"434","author":"Glasson","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.joca.2009.04.009_bib35","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/art.23027","article-title":"Double-knockout of ADAMTS-4 and ADAMTS-5 in mice results in physiologically normal animals and prevents the progression of osteoarthritis","volume":"56","author":"Majumdar","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2009.04.009_bib36","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/ncprheum0841","article-title":"Drug insight: aggrecanases as therapeutic targets for osteoarthritis","volume":"4","author":"Fosang","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.joca.2009.04.009_bib37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1042\/bss0700201","article-title":"Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors","volume":"70","author":"Nagase","year":"2003","journal-title":"Biochem Soc Symp"},{"key":"10.1016\/j.joca.2009.04.009_bib38","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/art.22427","article-title":"Increased collagen and aggrecan degradation with age in the joints of Timp3(-\/-) mice","volume":"56","author":"Sahebjam","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2009.04.009_bib39","first-page":"103","article-title":"Regulation of anabolic and catabolic gene expression in normal and osteoarthritic adult human articular chondrocytes by osteogenic protein-1","volume":"22","author":"Fan","year":"2004","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.joca.2009.04.009_bib40","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00264-007-0423-9","article-title":"OP-1\/BMP-7 in cartilage repair","volume":"31","author":"Chubinskaya","year":"2007","journal-title":"Int Orthop"},{"issue":"1","key":"10.1016\/j.joca.2009.04.009_bib41","first-page":"97","article-title":"A review of FGF18: its expression, signaling pathways and possible functions during embryogenesis and post-natal development","volume":"22","author":"Haque","year":"2007","journal-title":"Histol Histopathol"},{"issue":"7","key":"10.1016\/j.joca.2009.04.009_bib42","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.joca.2005.03.003","article-title":"Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis","volume":"13","author":"Moore","year":"2005","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2009.04.009_bib43","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jor.20325","article-title":"Binding and localization of recombinant lubricin to articular cartilage surfaces","volume":"25","author":"Jones","year":"2007","journal-title":"J Orthop Res"},{"key":"10.1016\/j.joca.2009.04.009_bib44","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/39807","article-title":"The capsaicin receptor: a heat-activated ion channel in the pain pathway","volume":"389","author":"Caterina","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.joca.2009.04.009_bib45","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pain.2007.07.026","article-title":"The roles of sodium channels in nociception: implications for mechanisms of pain","volume":"131","author":"Cummins","year":"2007","journal-title":"Pain"},{"key":"10.1016\/j.joca.2009.04.009_bib46","doi-asserted-by":"crossref","first-page":"8140","DOI":"10.1073\/pnas.120035997","article-title":"Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors","volume":"97","author":"Pesquero","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.joca.2009.04.009_bib47","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0162-3109(96)00101-4","article-title":"Nociception and inflammatory hyperalgesia in B2 bradykinin receptor knockout mice","volume":"33","author":"Boyce","year":"1996","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.joca.2009.04.009_bib48","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/ard.2007.080382","article-title":"Contrast-enhanced ultrasound in monitoring the efficacy of a bradykinin receptor 2 antagonist in painful knee osteoarthritis compared with MRI","volume":"68","author":"Song","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2009.04.009_bib49","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/sj.bjp.0707433","article-title":"Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain","volume":"152","author":"Jhaveri","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.joca.2009.04.009_bib50","first-page":"1330","article-title":"Knee effusions, popliteal cysts, and synovial thickening: association with knee pain in osteoarthritis","volume":"28","author":"Hill","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.joca.2009.04.009_bib51","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1136\/ard.54.5.398","article-title":"Innervation of the synovium","volume":"54","author":"Mapp","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2009.04.009_bib52","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nrd1693","article-title":"Osteoarthritis\u2014an untreatable disease","volume":"4","author":"Wieland","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.joca.2009.04.009_bib53","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/j.1476-5381.1995.tb15035.x","article-title":"Contribution of interleukin-1 beta to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia","volume":"115","author":"Safieh-Garabedian","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.joca.2009.04.009_bib54","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4081\/844","article-title":"Expression of NGF, Trka and p75 in human cartilage","volume":"47","author":"Gigante","year":"2003","journal-title":"Eur J Histochem"},{"key":"10.1016\/j.joca.2009.04.009_bib55","first-page":"617","article-title":"Nerve growth factor release by human synovial fibroblasts prior to and following exposure to tumor necrosis factor-alpha, interleukin-1 beta and cholecystokinin-8: the possible role of NGF in the inflammatory response","volume":"21","author":"Manni","year":"2003","journal-title":"Clin Exp Rheum"},{"key":"10.1016\/j.joca.2009.04.009_bib56","first-page":"S1206","article-title":"RN624 (Anti-NGF) improves pain and function in subjects with moderate knee osteoarthritis: a phase I study","author":"Lane","year":"2005","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2009.04.009_bib57","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1186\/ar1716","article-title":"Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial","volume":"7","author":"Spector","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.joca.2009.04.009_bib58","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/ar2315","article-title":"Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study","volume":"9","author":"Krzeski","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.joca.2009.04.009_bib59","article-title":"Protective effects of licofelone, a 5-lipoxygenase and cyclooxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multi-centre clinical trial using quantitative MRI","author":"Raynauld","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2009.04.009_bib60","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0140-6736(00)03610-2","article-title":"Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial","volume":"357","author":"Reginster","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.joca.2009.04.009_bib61","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1001\/archinte.162.18.2113","article-title":"Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study","volume":"162","author":"Pavelk\u00e1","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.joca.2009.04.009_bib62","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1002\/art.23973","article-title":"The effect of glucosamine and\/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine\/chondroitin arthritis intervention trial","volume":"58","author":"Sawitzke","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2009.04.009_bib63","article-title":"A two-year prospective, randomized, double-blind, controlled study assessing the effect of chondroitin 4&6 sulfate (CS) on the structural progression of knee osteoarthritis: STOPP (Study on osteoarthritis progression prevention)","author":"Reginster","year":"2006","journal-title":"Abstract ACR"}],"container-title":["Osteoarthritis and Cartilage"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458409001150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458409001150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:20:26Z","timestamp":1761016826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1063458409001150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":62,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S1063458409001150"],"URL":"https:\/\/doi.org\/10.1016\/j.joca.2009.04.009","relation":{},"ISSN":["1063-4584"],"issn-type":[{"value":"1063-4584","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"OA clinical trials: current targets and trials for OA. Choosing molecular targets: what have we learned and where we are headed?","name":"articletitle","label":"Article Title"},{"value":"Osteoarthritis and Cartilage","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joca.2009.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}